Next Phase Newsletter

A venture capital firm based in Boston is currently investing from its third fund of $220 million closed in 2015. The firm typically is the lead and first institutional investor in early-stage companies in the enterprise information technology (IT) space, including healthcare IT. The firm’s equity investment size ranges from $2-5 million. The firm is most active on the US East Coast and would consider opportunities from across the US. The firm plans to make 5-7 new investments in the following year

Within healthcare IT, the firm is seeking systems, technologies, and services that support clinical delivery to improve outcomes and efficiency of clinical care. The firm is not interested in consumer-facing products, genomic analytics, or life sciences software. The firm is looking for innovations that have demonstrated product-market fit in the form of recurring monthly revenue of $30K or more. Pre-revenue companies may be considered if there is a strong fit with its investment thesis. When it comes to healthcare IT investments, the firm often syndicates with strategic co-investors who understand the risks in the healthcare system, such as healthcare providers and payers.

The firm is looking for competent and experienced management teams with sector expertise. The firm brings in real world experience, industry knowledge and networks, and company-building skills to its portfolio companies. The firm takes a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

One of Europe’s largest venture capital firms is investing in life science companies through several funds which target seed, venture and growth-stage investments in European, North American and Asian companies. The initial investment size via these funds ranges from € 500K- € 10M and is in the form of straight equity. The firm is capable of leading or co-investing in financing rounds, however they prefer to have a local investor lead U.S. deals, unless it is a later-stage round (i.e. B, C, etc.) and the prior round was led by a U.S. investor. The firm has much more flexibility for European-based companies, and typically leads these rounds. The firm is aiming to make at least 6 more investments in 2016, with the average investment being € 3- € 5 M.

The firm takes a true venture approach to investing and prioritizes breakthrough technologies with a strong IP position. The firm is very interested in microbiome technologies and food technologies, and strongly believes in technologies at the intersection of food and pharma/biotech. Microbiome therapeutics and platforms are the primary interest, and the firm is willing to invest as early as pre-clinical in this subsector. As for other therapeutics preferred phase of development, typically only pre-clinical investments are made into companies with a platform technology, who aren’t relying on one therapeutic asset. Medical technology and connected health companies are also evaluated whatever the stage of development.

The firm prefers to work with mature, experienced management teams, but has no strict restrictions and is open to working with all entrepreneurs. The firm will invest in pre-revenue as well as revenue-generating companies, with maximum revenues of € 50M.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A multinational pharmaceutical company headquartered Japan with a subsidiary based in the USA is actively looking globally for opportunities to in-license cutting-edge, early stage therapeutic assets. Sponsored research may also be considered.

The firm’s external R&D is focused on both neurodegerative and neurodevelopmental diseases including Parkinson’s disease, autism, Rett Syndrome, fragile X, and lysosomal storage diseases. The firm is also interested in diabetes, immunology, and infectious diseases. The firm is seeking platform technology with new MOA such as gene therapy, stem cell therapy, and monoclonal antibody acting on new targets. The firm prefers early stage, pre-POC assets.

The firm is looking for assets that would be strategic a fit with its current portfolio. The firm is willing to negotiate regional rights based each therapeutic field. For example, in immunology and neurology, the firm would prefer both US and Asia rights. In diabetes, infectious diseases, and other areas, the firm can request Asia rights only.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A boutique venture capital firm based in California invests in growth and expansion-stage technology and life science companies. The firm closed its second fund in 2015, and prefers to make growth stage investments in Series B, C and D rounds, typically co-investing with other institutional investors. The firm leads about 30% of the investment rounds it takes part in, with allocation sizes varying according to the needs of the round. The firm focuses on companies located in Southern California and other regions undeserved by venture capital such as Utah, etc. The firm is actively seeking new investment opportunities, and anticipates that the second fund will invest in over 15 companies.

In the Life Sciences, the firm seeks to invest in diagnostics, therapeutics, and also selectively in medical device opportunities. The firm is opportunistic in terms of subsectors and indications, and generally seeks therapeutics that are at least in Phase III and diagnostics and medical devices that are very close to or with FDA approval. The firm historically invested in vitro diagnostic tests and medical imaging.
The firm generally co-invests with top tier institutional investors, and for companies based in Southern California the firm may act as a local lead investor to bring a syndicate together. MVP seeks companies with a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment firm based in Singapore manages a fund which was raised entirely from its two founders; therefore, the firm invests more similarly to an angel fund rather than a typical venture capital fund. The firm seeks to invest in seed and series A rounds and is sector agnostic. The firm is interested in the life sciences and has made one investment thus far. The firm typically invests USD 100K-500K per company. The firm looks to invest in companies that are based in Asia and is actively seeking new investment opportunities.

The firm is sector agnostic and will invest opportunistically across the life sciences. Given the firm’s investment size, the firm generally does not invest in technologies that are capital intensive, i.e. drug development. However, the firm may consider co-investing in larger deals if the opportunity is attractive.

The firm places great emphasis on the management team and seeks a strong and experienced management team with prior achievements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Europe-based family of multi-stage venture capital funds invests in life science companies with a focus on niche indications with verified technology. The firm can allocate up to €10-15M per company and typically provides equity as well as debt financing. The firm generally acts as the lead or co-lead investor and is open to invest in syndicates. Currently, the firm seeks to invest in companies that are based in the European Union or US company that is open for an EU entity. The firm is actively seeking new investment opportunities.

The firm is currently seeking to invest in innovative biotech therapeutics and pharmaceuticals with clear biology and verified technology. The firm is also interested in exceptional medical devices with a therapeutic application that is close to market or has generated some sales. The firm is opportunistic across the therapeutic subsectors but prefers products that target niche indications. Currently, the firm is more interested in oncology and orphan indications.

The firm requests a board seat in each portfolio company. The firm seeks a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A pharmaceutical company based in Korea is actively searching for innovative candidates and products around the world to incorporate into its pipeline and product portfolio. The firm has ample experience across various types of partnerships with overseas companies and is flexible in terms of the business structure. The firm is interested globally, including world-wide major territories.

The firm is currently seeking promising novel therapeutic candidates to incorporate into its pipeline. In terms of indications, the firm is indication agnostic with added interest in CNS, infection, oncology, and immunology. The firm is also interested in other therapeutic areas that address unmet medical needs, including orphan diseases. The firm prefers assets from IND ready to late stage development. The firm is also interested in obtaining distribution rights for innovative treatment in Phase III or in marketing authorization process.

The firm is open to working with companies anywhere in the world, and has no set requirements for partners; The firm is able to work with virtual drug companies by leveraging the firm’s own capabilities and third party relationships.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com